Monitor site activation and first patient dosing for RESTORE in September 2026 as the next major catalyst. The $50M ATM facility introduces overhang risk; watch for any share sales. Cash runway through 1H 2028 reduces near-term financing risk but does not eliminate it.
Price Chart
Executive Summary
NervGen Pharma reported Q2 2026 EPS of -$0.06, beating consensus of -$0.07 by 9.8%, but the company remains pre-revenue with no revenue reported. The key event is the upcoming Phase 3 RESTORE study initiation for NVG-291 in chronic spinal cord injury, with site activation expected in September 2026 and topline data in 1H 2028. The company has $61.1M in cash (post a $60M offering) to fund operations through that readout, but established a new $50M ATM facility post-quarter, adding dilution risk.
Key Financial Metrics
Key Facts
- EPS of -$0.06 beat consensus of -$0.07 by 9.8%
- No revenue reported; pre-revenue clinical-stage biotech
- Cash and cash equivalents of C$86.8M ($61.1M) as of June 30, 2026, up from C$22.1M ($16.1M) at Dec 31, 2025
- Completed $60M underwritten public offering in Q2 2026
- Established new $50M ATM facility post-quarter (July 2, 2026); no shares sold yet
- Phase 3 RESTORE study site activation expected September 2026; topline data anticipated 1H 2028
- Net loss of C$29.2M ($0.32/share basic) vs C$9.1M ($0.13/share) in Q2 2025, including C$19.4M non-cash warrant derivative loss
- R&D expenses rose to C$7.9M from C$2.7M YoY due to RESTORE start-up costs
Financial Impact
Net loss of C$29.2M in Q2 2026, primarily driven by a C$19.4M non-cash warrant derivative loss; cash burn rate increasing with RESTORE initiation
Risk Factors
- Clinical trial failure or delay in RESTORE
- Dilution from ATM facility if shares are sold
- Increasing R&D spend may accelerate cash burn
- Pre-revenue company with no approved products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344403 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 6-K | $1.88 $1.81 | ▲ +3.72% | ▲ +4.93% | $1.52 (+19.15%) |
Sep 25, 2026 4w ago | Press Release | $1.88 $1.81 | ▼ −3.72% | ▼ −4.93% | $1.52 (−19.15%) |
Sep 24, 2026 4w ago | 6-K | $2.02 $1.76 | ▼ −12.87% | ▼ −12.46% | $1.52 (−24.75%) |
Aug 13, 2026 10w ago | 6-K | $1.76 $1.76 | · 0.00% | ▲ +1.96% | $1.52 (−13.64%) |
Aug 13, 2026 10w ago | Press Release | $1.76 $1.76 | · 0.00% | ▲ +1.96% | $1.52 (−13.64%) |
Jul 2, 2026 16w ago | 6-K | $2.12 $1.86 | ▲ +12.26% | ▲ +13.19% | $1.52 (+28.30%) |
Jun 1, 2026 21w ago | 6-K | $2.00 $1.81 | ▲ +9.50% | ▲ +6.54% | $1.52 (+24.00%) |
May 27, 2026 21w ago | EFFECT | $2.07 $1.91 | ▼ −7.73% | ▼ −8.20% | $1.52 (−26.57%) |
May 26, 2026 21w ago | 6-K | $2.07 $2.00 | ▼ −3.38% | ▼ −4.59% | $1.52 (−26.57%) |
May 22, 2026 22w ago | 6-K | $2.13 $2.00 | ▲ +6.10% | ▲ +7.32% | $1.52 (+28.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers